Scientists, of course, did not start with a clean slate: in based on the achievements of previous years. For example, triazavirin, developed several years ago in Yekaterinburg at the Institute of organic synthesis UB RAS group under the leadership of academician Vladimir Chekhonin. Now researchers have proposed a new – inhalation form of the drug acting directly on the coronavirus.
according to experts, long-standing practices give a great advantage: it is easier to establish industrial production and ensure required volumes. But the legacy of past years donated and cons: rare pharmaceutical companies in the country now has a complete industrial chain for production of new and already known drugs. Most of the substances purchased abroad, mostly in China and India.
– As shown by the pandemic, the dependence in the field of pharmacology threatens the pharmaceutical safety of the country. The Institute of drugs recently reviewed the list of essential drugs, to understand the strategic stock of any substances necessary for the state. And provide the prospect of import substitution, – said the first Deputy Minister of industry and trade of the Russian Federation Sergey Tsyb at the recent session of Innoprom dedicated to the strategy of development of pharmacology.
representatives of the largest pharmaceutical companies in the country in the course of the session shared recent dramatic stories of supply of substances.
– the Problems began in February when, one after another in China began to close the factories – suppliers of raw materials. We tried to make maximum margin. In refrigerators dovozil substance to the borders of China, then were loaded into our trucks and delivered to the plants. Believed that the ensured supply of raw materials for some items for almost a year, – said Sergey Klykov, the General Director of “farm-Centre”, the managing organization of the company “Synthesis”.
But, as life has shown, due to the increased demand the entire amount was gone in three months. And to continue the production of drugs had to solve the question of the purchase of the substance from an alternative manufacturer. Traditionally, the procedure for changing supplier in the field of pharmacology is months, the pandemic has accelerated the process: the goods urgently re-registered, to adjust the timing of the procedures has made changes to the legislation.
Production sites of fusion are located in several regions, one of the main – in the Kurgan region. Due to the quick change of supplier, the company even increased its power. Now it produces at least half a dozen drugs are included in the recommendations of the Ministry of health for the treatment COVID-19. One and a half times increased production of antibiotics.
But the main pride of the company – here, in spite of difficulties with raw material supply, have managed to build up at night.to the drug hydroxychloroquine. For a long time this drug was considered effective for a narrow range of diseases. On the “Synthesis” of his in the past released, but in small quantities – up to 4 thousand units per year. Now, when the drug is recognized effective against the coronavirus, the company has managed hundreds of times to increase the volume of April is already released 700 thousand packages. To saturate the demand for more open platforms, including the first batch released in the Mound.
Mobilization, of course, a powerful engine of progress, but experts are sure it is necessary to change strategy of development of pharmaceutical industry for the country were not in drug dependence from other States. A cautionary tale about how in the midst of a pandemic COVID-19 had to save hundreds of thousands of patients with diabetes in Venezuela, said the General Director of “GEROPHARM” Petr Rodionov. Vital for diabetes drug in the country is not made, the main suppliers are US companies refused contracts. Had the planes to deliver the insulin from Russia.
One of the main conclusions that are made and international corporations, and in the pharmaceutical industry need to move away from globalization and at the forefront to put national interests – said Rodionov.
Now the government discusses a proposal to create a state reserve substances at least essential drugs. Domestic producers of this project are twofold. On the one hand, a strategic reserve of drugs is really needed. On the other – why spend huge sums on purchases abroad, not efficient to invest in the development of production in their territory?
– If at least part of the money that will be spent on the state reserve to allocate subsidies to the companies on a competitive basis will apply and in case of victory will build factories for the production of substances on the territory of the Russian Federation, it will bring greater effect. In two years it will be possible to establish an uninterrupted production of a very wide range. And the growth will not 60 percent, as stipulated in the state program, and 500. And drug safety of the country will be provided, – said Petr Rodionov.
More recently, Irbit pharmaceutical plants created in the years of the great Patriotic war, was the only one in the Urals enterprise, retaining the production of substances for drugs, most of which were included in the list of vital. In the country of such plants, adhering to Soviet technology that was no more than 50. By 2019, according to the Ministry of industry and trade of the Russian Federation, their number increased almost two times – to 95. Over the last five years in the country, 60 percent have increased the volume of production of pharmaceutical substances. Even before the current extraordinary situation, it was clear that this new technologicalSkye-based development, and other competencies that give the possibility to regulate the cost of production of drugs throughout the supply chain.
– This approach will not only ensure the production safety of the country, but also become more competitive in the international market – said the Director of the state Institute for drugs and good practices Vladislav Shestakov.
All the materials of the story “COVID-19. We can do it!” read the .
